Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can pomegranate seed oil cut infections in dementia patients?

NCT ID NCT07432763

Disease control Sponsor: Panhellenic Federation of Alzheimer's Disease and Related Disorders Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving pomegranate seed oil supplements for 24 weeks could help prevent urinary tract infections and pneumonia in people with advanced dementia who are in palliative care. It also checked if the supplement helped reduce or stop antipsychotic medications. The trial included 18 participants and compared the supplement to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pomegranate seed oil
What this could lead to
If it works, this could offer a simple, natural way to reduce infections and antipsychotic use in advanced dementia patients.
What could go wrong
This is a very small, completed trial with only 18 participants. Results may not apply to larger groups, and supplements are not a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

May 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 65+ * Dementia diagnosis (major neurocognitive disorder) according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11) * Participants classified as Stage 7, Profound Cognitive Decline on the Global Deterioration Scale, corresponding to advanced dementia * AD related biomarkers in CSF * Caregiver consent for study participation Exclusion Criteria: * History of allergy to the supplement or any of its components * Prior diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11) * Participants having medical history of recurring urinary tract infections * Participants having medical history of renal or liver failure * Participants concurrently participating in other clinical studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection dementia substance withdrawal syndrome urinary tract infections, recurrent, susceptibility to pneumonia prevention target urinary tract infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antipsychotics discontinuation Antipsychotics tapering Urinary tract infection, recurrent Urinary tract infections (UTIS)

Contacts and locations

Locations

  • Palliative Care Centre "Panagia Glykofilousa"

    Thessaloniki, Central Macedonia, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.